ArticleCancer & metabolism2026
Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue.
Article in Cancer & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03560479 (A Randomized Placebo Controlled Phase I/II Study Evaluating the Safety and Efficacy of alpha1H in Adult Patients With Non-muscle Invasive Bladder Cancer Awaiting Transurethral Surgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Placebo Controlled Phase I/II Study Evaluating the Safety and Efficacy of alpha1H in Adult Patients With Non-muscle Invasive Bladder Cancer Awaiting Transurethral Surgery
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunctions are associated with increased cancer morbidity and rapid tumor progression. The alpha1-oleate complex has been used successfully to treat bladder cancer in a placebo-controlled Phase II study. Studies of the related BAMLET complexes recently identified effects on metabolism, suggesting additional functions of the "HAMLET family" of tumoricidal complexes.
aimsTo investigate if intravesical alpha1-oleate treatment affects metabolism in bladder cancer tissue. MATERIALS AND
methodsSamples were obtained from patients with NMIBC, enrolled in a placebo-controlled study of intravesical alpha1-oleate treatment [1]. Cells shed into the urine were harvested at each instillation and biopsies obtained at TURBT after six instillations of alpha1-oleate. The shed cells and biopsies were subjected to RNA sequencing and genome-wide transcriptomic analysis, and urine samples were analyzed using adipokine arrays.
resultsRNA sequencing detected significant inhibition of metabolic genes and networks in shed cells and tissue biopsies from alpha1-oleate treated patients, compared to the placebo group. Genes and gene networks regulating glucose and lipid synthesis were inhibited in alpha1-oleate treated patients, including ADIPOQ, which encodes the lipid- and glucose-regulating protein adiponectin and LEP, which encodes the metabolism and fat storage regulator Leptin. Leptin was further identified as an upstream regulator of the adiponectin response to alpha1-oleate and LEP and ADIPOQ networks showed strong interconnection in treated tissues. Analysis of shed tumor cells, suggested rapid kinetics of the metabolic response and urine levels of adiponectin and leptin were increased post-treatment, compared to pre-treatment samples and the shed tumor cells in urine contained adiponectin and leptin, as shown by immunohistochemistry.
conclusionsThe findings identify potent local effects of alpha1-oleate treatment on tumor metabolism, after intravesical instillation. The metabolic regulators adiponectin and leptin were affected in tumor tissue and cells containing adiponectin and leptin were shed into the urine, potentially depleting the tumor of cells with high adipokine levels. These potent effects suggest a new molecular approach for targeting and inhibiting key regulators of cancer metabolism in superficial tumors.
trial registrationDoubleblinded Phase I/II clinical trial (EudraCT 201600426914 NCT03560479, Registration Date 20180521).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.